180 related articles for article (PubMed ID: 15082027)
1. Chronic exposure to tolbutamide and glibenclamide impairs insulin secretion but not transcription of K(ATP) channel components.
Ball AJ; McCluskey JT; Flatt PR; McClenaghan NH
Pharmacol Res; 2004 Jul; 50(1):41-6. PubMed ID: 15082027
[TBL] [Abstract][Full Text] [Related]
2. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.
Sunaga Y; Gonoi T; Shibasaki T; Ichikawa K; Kusama H; Yano H; Seino S
Eur J Pharmacol; 2001 Nov; 431(1):119-25. PubMed ID: 11716850
[TBL] [Abstract][Full Text] [Related]
3. Functional analysis of six Kir6.2 (KCNJ11) mutations causing neonatal diabetes.
Girard CA; Shimomura K; Proks P; Absalom N; Castano L; Perez de Nanclares G; Ashcroft FM
Pflugers Arch; 2006 Dec; 453(3):323-32. PubMed ID: 17021801
[TBL] [Abstract][Full Text] [Related]
4. Effects of sulphonylureas and diazoxide on insulin secretion and nucleotide-sensitive channels in an insulin-secreting cell line.
Sturgess NC; Kozlowski RZ; Carrington CA; Hales CN; Ashford ML
Br J Pharmacol; 1988 Sep; 95(1):83-94. PubMed ID: 3146398
[TBL] [Abstract][Full Text] [Related]
5. Dissociation of KATP channel and sulphonylurea receptor in the rat clonal insulin-secreting cell line, CRI-D11.
Khan RN; Hales CN; Ozanne SE; Adogu AA; Ashford ML
Proc Biol Sci; 1993 Sep; 253(1338):225-31. PubMed ID: 7694299
[TBL] [Abstract][Full Text] [Related]
6. Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity.
Kawaki J; Nagashima K; Tanaka J; Miki T; Miyazaki M; Gonoi T; Mitsuhashi N; Nakajima N; Iwanaga T; Yano H; Seino S
Diabetes; 1999 Oct; 48(10):2001-6. PubMed ID: 10512365
[TBL] [Abstract][Full Text] [Related]
7. Carriers of an inactivating beta-cell ATP-sensitive K(+) channel mutation have normal glucose tolerance and insulin sensitivity and appropriate insulin secretion.
Huopio H; Vauhkonen I; Komulainen J; Niskanen L; Otonkoski T; Laakso M
Diabetes Care; 2002 Jan; 25(1):101-6. PubMed ID: 11772909
[TBL] [Abstract][Full Text] [Related]
8. Regulated expression of adenosine triphosphate-sensitive potassium channel subunits in pancreatic beta-cells.
Moritz W; Leech CA; Ferrer J; Habener JF
Endocrinology; 2001 Jan; 142(1):129-38. PubMed ID: 11145575
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
Hu S; Wang S; Fanelli B; Bell PA; Dunning BE; Geisse S; Schmitz R; Boettcher BR
J Pharmacol Exp Ther; 2000 May; 293(2):444-52. PubMed ID: 10773014
[TBL] [Abstract][Full Text] [Related]
10. Desensitization of sulphonylurea- and nutrient-induced insulin secretion following prolonged treatment with glibenclamide.
Ball AJ; Flatt PR; McClenaghan NH
Eur J Pharmacol; 2000 Nov; 408(3):327-33. PubMed ID: 11090651
[TBL] [Abstract][Full Text] [Related]
11. Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets.
Panten U; Burgfeld J; Goerke F; Rennicke M; Schwanstecher M; Wallasch A; Zünkler BJ; Lenzen S
Biochem Pharmacol; 1989 Apr; 38(8):1217-29. PubMed ID: 2650685
[TBL] [Abstract][Full Text] [Related]
12. Taurine block of cloned ATP-sensitive K+ channels with different sulfonylurea receptor subunits expressed in Xenopus laevis oocytes.
Lim JG; Lee HY; Yun JE; Kim SP; Park JW; Suh SI; Jang BC; Cho CH; Bae JH; Kim SS; Han J; Park MJ; Song DK
Biochem Pharmacol; 2004 Sep; 68(5):901-10. PubMed ID: 15294453
[TBL] [Abstract][Full Text] [Related]
13. Sulphonylurea receptor-1, sulphonylureas and amplification of insulin secretion by Epac activation in β cells.
Nenquin M; Henquin JC
Diabetes Obes Metab; 2016 Jul; 18(7):698-701. PubMed ID: 26584950
[TBL] [Abstract][Full Text] [Related]
14. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions.
Gribble FM; Reimann F
J Diabetes Complications; 2003; 17(2 Suppl):11-5. PubMed ID: 12623163
[TBL] [Abstract][Full Text] [Related]
15. An abundant, truncated human sulfonylurea receptor 1 splice variant has prodiabetic properties and impairs sulfonylurea action.
Schmid D; Stolzlechner M; Sorgner A; Bentele C; Assinger A; Chiba P; Moeslinger T
Cell Mol Life Sci; 2012 Jan; 69(1):129-48. PubMed ID: 21671119
[TBL] [Abstract][Full Text] [Related]
16. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Pearson ER; Flechtner I; Njølstad PR; Malecki MT; Flanagan SE; Larkin B; Ashcroft FM; Klimes I; Codner E; Iotova V; Slingerland AS; Shield J; Robert JJ; Holst JJ; Clark PM; Ellard S; Søvik O; Polak M; Hattersley AT;
N Engl J Med; 2006 Aug; 355(5):467-77. PubMed ID: 16885550
[TBL] [Abstract][Full Text] [Related]
17. Sulphonylureas do not increase insulin secretion by a mechanism other than a rise in cytoplasmic Ca2+ in pancreatic B-cells.
Garcia-Barrado MJ; Jonas JC; Gilon P; Henquin JC
Eur J Pharmacol; 1996 Mar; 298(3):279-86. PubMed ID: 8846827
[TBL] [Abstract][Full Text] [Related]
18. Glibenclamide-induced apoptosis is specifically enhanced by expression of the sulfonylurea receptor isoform SUR1 but not by expression of SUR2B or the mutant SUR1(M1289T).
Hambrock A; de Oliveira Franz CB; Hiller S; Osswald H
J Pharmacol Exp Ther; 2006 Mar; 316(3):1031-7. PubMed ID: 16306272
[TBL] [Abstract][Full Text] [Related]
19. Location of the sulphonylurea receptor at the cytoplasmic face of the beta-cell membrane.
Schwanstecher M; Schwanstecher C; Dickel C; Chudziak F; Moshiri A; Panten U
Br J Pharmacol; 1994 Nov; 113(3):903-11. PubMed ID: 7858884
[TBL] [Abstract][Full Text] [Related]
20. Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels.
Hansen AM; Hansen JB; Carr RD; Ashcroft FM; Wahl P
Br J Pharmacol; 2005 Feb; 144(4):551-7. PubMed ID: 15678092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
